AMS
American Shared Hospital Services
AMS has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
AMS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Weak |
AMS's revenue and cash flow are currently healthy, but its profitability and balance sheet are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
AMS PE Valuation
AMS has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
AMS Forward outlook
There aren't enough analyst estimates for AMS to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
AMS Earnings Per Share
AMS and NVO do not have enough comparable growth data to identify a winner.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
AMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.4M | +19% |
| Q1 2026 | $7.1M | +16% |
| Q4 2025 | $7.7M | -15% |
| Q3 2025 | $7.2M | +2.5% |
| Q2 2025 | $7.1M | +0.2% |
| Q1 2025 | $6.1M | +17% |
| Q4 2024 | $9.1M | +59% |
| Q3 2024 | $7M | +36% |
AMS has the edge over NVO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -11% | -3.1 points |
| Q1 2026 | -13% | +8.2 points |
| Q4 2025 | -18% | +2.1 points |
| Q3 2025 | -4.8% | +7.9 points |
| Q2 2025 | -7.7% | -7.7 points |
| Q1 2025 | -21% | -20 points |
| Q4 2024 | -20% | -27 points |
| Q3 2024 | -13% | -14 points |
AMS's operating margin was −11% last quarter, down 3.1 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over AMS on profitability, with a higher operating margin.
AMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $2.2M | +$4.5M |
| Q1 2026 | $2.1M | +$3.6M |
| Q4 2025 | $1.3M | +$5.7M |
| Q3 2025 | -$2M | -$1.6M |
| Q2 2025 | -$2.3M | -3347% |
| Q1 2025 | -$1.5M | +$1.5M |
| Q4 2024 | -$4.4M | -$1.2M |
| Q3 2024 | -$407K | -$356K |
AMS's free cash flow has turned positive after two years mostly in the red: $4M over the past year.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over AMS on cash flow, with more consistent year-over-year improvement.
AMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.2% | +147K shares |
| 1 year | +4.4% | +290K shares |
| 3 years | +8.5% | +536K shares |
| 5 years | +18% | +1.1M shares |
| Available history | +16% | +964K shares |
AMS has 7M diluted shares, up 4.4% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over AMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
AMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 5.3x | High |
| Q1 2026 | 5.1x | High |
| Q4 2025 | 6.5x | High |
| Q3 2025 | 6.3x | High |
| Q2 2025 | 4.7x | High |
| Q1 2025 | 3.8x | Elevated |
| Q4 2024 | 2.7x | Moderate |
| Q3 2024 | 0.1x | Very low |
AMS's net debt is about 5.3 years of its operating earnings (EBITDA), up from 4.7 years a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over AMS on leverage, with a lower net debt burden relative to earnings.
AMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.1 | Neutral |
| Stochastic | 11.8 | Oversold |
AMS's weekly RSI is 30 (neutral) and its Stochastic is 12 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
AMS PE vs Healthcare Sector
| Metric | AMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
AMS has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
AMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.28 | 15% below |
| 20 week MA | $1.39 | 22% below |
| 50 week MA | $1.66 | 34% below |
| 100 week MA | $2.15 | 49% below |
| 200 week MA | $2.51 | 57% below |
AMS is in a downtrend: it's below all five of its weekly moving averages, and 57% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over AMS on trend strength, trading above more of its moving averages.
AMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.56 | $2.10 | -18% |
| 2021 | $2.10 | $2.42 | +15% |
| 2022 | $2.42 | $2.81 | +16% |
| 2023 | $2.81 | $2.38 | -15% |
| 2024 | $2.38 | $3.19 | +34% |
| 2025 | $3.19 | $2.14 | -33% |
| 2026 YTD | $2.14 | $1.09 | -49% |
AMS has finished lower in three of the last six years. It's down 49% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over AMS on returns for 2026, with the stronger performance.